New research suggests that higher global temperatures could have prompted an adaptation in Candida auris, allowing it to infect warm-blooded mammals.
Browsing: Candida auris
Results from the Centers for Disease Control and Prevention has provided insights into why Candida auris outbreaks frequent in healthcare facilities.
We look at some of the highlights of our Twitter chat (#TalkFungi), where we questioned Ilan Schwartz, Andrej Spec, Rebecca Drummond and Jessie Uehling about all things mycology.
In this interview, we speak to Ana Litvintseva, a Medical Mycologist and Team Lead at the Centers for Disease Control and Prevention (CDC; GA, USA) about Candida auris, its emergence and the challenges it presents.
Multi-use patient equipment, such as thermometers, has been linked to one of the largest outbreaks of the emerging drug-resistant fungal pathogen Candida auris to-date.
Results from the Phase II STRIVE trial demonstrates favorable safety, tolerability and efficacy of the antifungal drug, rezafungin.
To round up 2017, we asked our Expert panel to choose their top papers from the year. Here, you can discover these articles and the reasons why they were chosen.
New drugs with antifungal action need to be developed. Here, the authors investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp.
A novel CRISPR–Cas9-based gene drive platform has been developed by researchers and may help us understand some of the genetic networks underlying virulence in fungal pathogen, Candida albicans.
Public Health England has released updated guidance on Candida auris, as they confirm that over 200 patients have been infected or colonized with the fungus.